Chapter 38: Antibiotics That Inhibit Bacterial Cell Wall Synthesis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today we are not just talking about medicine.

We are talking about what is, I think, the single greatest pivot point in human history.

That's a big claim.

It is.

But think about it.

We're talking about the difference between a world where, you know, a scratched knee from playing in the garden could lead to a funeral three days later and the world we all live in today.

OK, when you put it like that, it's not hyperbole at all, is it?

We are looking at the foundation of modern survival antibiotic.

Exactly.

And specifically the ones that target the bacterial cell wall.

The originals, the big guns.

And to guide us through this, we are doing a deep dive into Chapter 38 of Brunner and Stevens Pharmacology, sixth edition.

The chapter is titled Antibiotics That Inhibit Bacterial Cell Wall Synthesis.

And it is a dense chapter.

I won't lie to you.

It is packed.

You open it up and you see diagrams, chemical structures, a lot of Greek and Latin roots.

This should be intimidating.

It can be.

But it is arguably one of the most important chapters in the entire book.

I mean, these drugs, the penicillins, the cephalosporins, vancomycin, they have been the backbone of antimicrobial chemotherapy for over 70 years.

70 years, seven decades.

And yet when I was reading through this, the text makes it clear right from the get go.

We are still using them.

But the ground is it's shifting under our feet.

We're in an arms race.

We absolutely are.

The text highlights that despite the massive and I mean massive growing problem of microbial resistance,

these cell wall inhibitors remain incredibly widely used.

So our mission today is to walk through this chapter systematically.

We aren't just going to list drugs.

We need to decode the battlefield, which is the bacterial cell envelope.

Then we need to understand the weaponry, which is the chemistry of these drugs.

And finally, the safety protocols, the pharmacology and the risks.

Exactly.

I love the battlefield analogy.

And honestly, reading through this chapter, it feels like military strategy.

You know, you have to know the enemy's fortress before you can figure out how to blow it up.

A perfect analogy.

So let's start there.

Section one, the battlefield.

The text directs us immediately to figure 38 .1, which compares the cell envelopes of gram positive and gram negative bacteria.

Now I usually just think of this as, you know, purple stain versus pink stain on a lab slide.

But biologically, what are we actually looking at?

You're looking at two completely different survival strategies.

It really is the difference between wearing a big, thick suit of armor and having like a high tech force field.

Okay.

I like that.

Let's start with the armor.

Gram positive.

Let's look at the gram positive bacteria first.

You're a Staphylococci, you're a Streptococci.

The text describes this as having a cytoplasmic membrane surrounded by a cell wall.

But the key characteristic here is the thickness of that wall.

Right.

It looks huge in the diagram.

It is.

Imagine a heavy hand knitted wool sweater,

a really, really thick one.

That is the gram positive cell wall.

It is a massive multi -layered meshwork of something called peptidoglycan.

Okay.

So a big, thick wall.

That sounds like it would be harder to penetrate intuitively.

You would think so, wouldn't you?

But think about a knitted sweater.

It's thick, sure, but it's porous.

It's absolutely full of holes.

If you dunk a bucket of water on someone wearing a sweater, they get wet immediately.

Chemically, that thick wall is actually quite water -soluble drugs, nutrients.

Everything just soaks right through to the membrane underneath.

So gram positive is thick but sponge -like, simply enough.

But then you look at the gram negative bacteria in the figure, it looks completely different.

It's so much more complex.

It is completely different.

The peptidoglycan wall, that sweater layer,

is incredibly thin in gram negatives.

I mean, maybe only one or two layers deep.

That's it.

That's it.

But, and this is the aha moment in the chapter.

It compensates for that thin wall by having a second membrane outside the wall called the outer membrane.

So gram positive is one membrane and a thick wall.

Gram negative is a membrane, a thin wall, and then another membrane.

It's a sandwich.

A very dangerous sandwich.

That outer membrane is a complex barrier.

The book calls it a trilaminar membrane, meaning it has three layers, and the outer face contains these molecules called lipopolysaccharides, or LPS.

And the text flags this LPS as endotoxin.

That sounds ominous.

Is that just a fancy name for poison?

In a way, yes.

But it's very specific.

The text points to a component of LPS called lipid A.

This is absolutely crucial for you to understand because it explains why gram negative infections are so scary.

Okay.

Lipid A is the endotoxin responsible for gram negative sepsis.

When that outer membrane breaks apart, maybe because our immune system killed the bug or because our antibiotics did, lipid A is released into the bloodstream.

And what does it do?

It triggers the immune system to go completely nuclear.

The text lists the effects.

You get a high fever.

You get platelet aggregation.

So your blood starts clotting where it shouldn't.

And crucially, increased vascular permeability.

Vascular permeability.

That means blood vessels get leaky.

Exactly.

Fluid just pours out of the vessels into the tissues.

Your blood pressure crashes.

That is septic shock.

It's what makes a gram negative infection potentially lethal in a very systemic, very rapid way.

So the gram negative bacteria have this extra shield that is also a biological weapon.

Okay.

But this brings up a logistical question.

If they have this outer shield, this force field, how do they get nutrients in?

Or more importantly for us, how do we get drugs in?

That's where pour ins come in.

The text describes pour ins as these little protein channels.

And they're embedded in that outer membrane.

Think of them as the airlocks or the gates in force field.

They let ions and small molecules pass through.

And I assume our antibiotics have to sneak through those gates.

Exactly.

They have to.

And this is a key point for resistance later on, something the chapter brings up.

It notes that if a bacterium alters the structure of its pour ins,

if it basically changes the shape of the keyhole, then some drugs like imipenem can't get inside.

It effectively just locks the gate on us.

It locks the gate.

Okay.

So that's the outer geography.

We have the sponge -like gram positives and the armored sandwich gram negatives.

But the chapter focuses on cell wall synthesis inhibitors.

So let's zoom in on the wall itself.

The text gets into some heavy biochemistry here.

N -acetylmuramic acid, D -alanine, pentaglycine bridges.

It feels like a lot of jargon.

Can we strip this down?

What is the actual engineering problem the bacterium is trying to solve with this wall?

The problem is pressure.

Massive, massive pressure.

Pressure from where?

From osmosis.

The inside of a

It's a very concentrated, soupy environment.

The outside world, our blood or a puddle of water, is usually hypoconic.

It's much more watery.

So basic biology dictates that water wants to rush into the cell to balance things out.

Constantly.

Nonstop.

If you are a bacterium, you are basically an overinflated balloon living in a world of pins.

The internal pressure is huge.

Without a rigid casing to hold it all together, the water would rush in, the cell would swell up, and it would just pop.

And that popping is what the text calls osmotic lysis.

Precisely.

So, to prevent exploding, the bacterium build the cage.

That cage is peptidoglycan.

Think of it as a polymer mesh.

The text breaks down the chemistry.

It's constructed from repeating desaccharide units.

Two sugars.

Anacetylglucosamine, or GLC -ANAC,

and anacetylmuramic acid, or MIRNAC.

GLC -ANAC and MIRNAC.

They sound like the names of two alien constructicons from a cartoon.

They do.

But they are the bricks of the wall.

Imagine long chains of these sugars alternating.

GLC -ANAC, MIRNAC, GLC -ANAC, MIRNAC.

Like long metal rods.

But a stack of rods just falls over if you don't have mortar or wire to tie them together.

And that's the peptido part of peptidoglycan.

A peptide part.

Yes, exactly.

Attached to each of those MIRNAC molecules is a peptide side chain.

And the text specifies that this chain contains two very important molecules of D -alanine and a pentaglycine side chain.

Okay, so we have sugar rods and peptide twist ties.

But how does it all become a solid wall?

A rigid structure.

Crosslinking.

This is the crucial moment.

And it's described beautifully in figure 38 .2.

You have these strands of sugars and peptides just floating near each other.

To lock them together, a reaction occurs called the transpeptidase reaction.

Transpeptidase?

Yes.

The glycine pentapeptide of one strand bonds to the D -alanine of another strand.

It's like tying the knots in a net.

Precisely.

And in the process, a terminal D -alanine is removed.

This crosslinking, this knot tying, gives the wall its structural integrity.

It turns a pile of loose chains into a rigid protective mesh.

So these drugs are about to discuss.

They are basically just sabotaging this construction site so the bacteria explode from their own internal pressure.

That is exactly what they're doing.

And the absolute beauty of it, as the chapter points out, is selective toxicity.

Right.

Humans don't have cell walls.

We have cell membranes, sure, but no peptidic ligand.

So inhibiting this process doesn't hurt our cells directly.

It's a sniper shot at the bacteria.

Okay.

Let's talk about how we sabotage this wall.

Section two of our outline is mechanisms of sabotage.

We have the beta -lactams and the non beta -lactams.

Let's start with the beta -lactams since they are clearly the stars of the show.

They are.

The beta -lactams include penicillins, cephalosporins, carbapenems, and model bactams.

Their mechanism is very specific, very elegant.

Remember those enzymes that build the wall, the ones tying the knots?

The text calls them penicillin binding proteins, or PVPs, which is a very convenient name, by the way.

Very helpful.

Very helpful, yes.

These PVPs are the construction workers.

They're enzymes that are anchored in the cytoplasmic membrane, and their job is to perform that cross -linking transpeptidase reaction we just talked about.

Okay.

Beta -lactam antibiotics look structurally similar to the D -alanine tail of the wall.

They are molecular mimics.

They're decoys.

So the construction worker, the PBP, thinks it's grabbing a brick, but it accidentally grabs the drug instead.

Exactly.

And here is the kicker.

The beta -lactams form a covalent bond with the PBPs.

A covalent bond.

That's a strong bond, right?

That's not just a handshake.

It's essentially permanent in the biological world.

It's irreversible.

They handcuff the construction workers.

The text says this inhibition prevents elongation or cross -linking of the peptidoglycan.

So what's the result?

The result is that the bacterium stops growing, or ditalysis occurs, it digests itself from the inside out, or it turns into a spheroplast, which is a cell without a wall.

Just a wobbly, unstable blob.

Total construction failure.

Now the outline also mentions non -beta -lactams that attack the wall.

The text lists bacitracin, phosphomycin, and vancomycin.

Figure 38 .2 breaks this down like an assembly line.

Let's walk through that line.

Where does phosphomycin hit?

Phosphomycin hits at the very, very beginning, way back in the factory.

Step one of building the wall is making the precursor bricks inside the cell's cytoplasm.

Okay.

Phosphomycin inhibits an enzyme called anal -poruvial transferase.

This prevents the formation of UDP myrnac.

In simple terms, it stops the bricks from even being molded.

Okay, so phosphomycin stops the brick factory.

Got it.

What about bacitracin?

Bacitracin attacks the logistics chain.

The building blocks are made inside the cell, but the wall is built outside the cell.

They need to be transported across the membrane.

There's a carrier molecule for this.

A lipid carrier called bactoprenol pyrophosphate.

Think of it as a little truck that ferries the bricks across the river from the factory to the construction site.

And bacitracin?

Bacitracin blows up the truck.

Technically, it blocks the dephosphorylation of bactoprenol, which means the carrier can't be recycled to go back and pick up more bricks.

The entire logistics chain just collapses.

No bricks at the site, no wall.

It makes sense.

And finally, vancomycin.

Vancomycin works at the site of construction, but differently than the beta -lactams.

Remember, the beta -lactams handcuff the worker, the PBP enzyme.

Right.

Vancomycin ignores the worker and goes for the material.

It binds tightly, very tightly, to that de -alanine tail of the pepto -glycan precursor.

So it basically covers the docking port on the block.

Exactly.

It's like putting a cap on the end of a Lego piece so nothing can snap onto it.

It physically blocks the cross -linking from happening.

So we have three very different ways to cause the same catastrophic failure of the cell wall.

Right.

We've surveyed the battlefield and we know the sabotage methods.

Now, let's get into the specific weapons.

Section three,

the first wave, penicillins.

The classic.

The absolute classic.

The text gives a nod to Alexander Fleming, of course, who discovered penicillin in mold, juice, penicillium fungus contaminating his cultures back in the late 1920s.

The famous story.

It is.

But the book importantly credits Chain and Flory for developing the methods for mass production during World War II.

That's when it really changed the world.

We went from scraping mold off a Petri dish to treating wounded soldiers on the front lines.

Let's look at the chemistry here.

Figure 38 .3 shows the core structure.

It looks kind of like a little house with a garage attached to it.

That's a good way to see it.

It is a double ring structure.

You have the beta -lactam ring fused to a phiazolidine ring and then attached to the house is a side chain, which is labeled the R group.

That R group is the variable.

It's what distinguishes one type of penicillin from another.

And the text makes a big deal about pharmacokinetics here, specifically absorption and this acid issue.

Why is acid such a big deal for these drugs?

Because the stomach is a vat of hydrochloric acid and that beta -lactam ring, the business end of the molecule, is chemically fragile.

Some penicillins are what we call acid label.

Label meaning unstable.

Unstable, yes.

Stomach acid breaks that ring open and destroys the drug before it ever gets into your blood.

So you can't swallow those.

They'd be useless.

Right.

Pipercillin is an example given in the text.

It must be injected parentally, so IV or IM.

Others, like amoxicillin and penicillin V, were chemically tweaked by adding different R groups to be acid stable so they can survive the stomach and be taken as oral pills.

This distinction dictates how a doctor prescribes them.

And what about where they go in the body?

The text mentions the CNS, the central nervous system, as a special case.

Generally, penicillins are great at distributing throughout the body.

They go almost everywhere, except they can't cross the blood -brain barrier.

They don't get into the CNS.

However, there is a massive exception, and it's shown in figure 38 .4.

The inflamed meninges.

Yes.

When the meninges, which are the lining of the brain, are inflamed, as in bacterial meningitis, the barrier becomes leaky.

The permeability changes.

And suddenly, penicillin can penetrate.

That is such a fascinating physiological quirk.

The disease itself opens the door for the cure to get in.

It is absolutely vital.

It allows high -dose intravenous penicillin to be effective for treating bacterial meningitis.

What about getting rid of them?

Excretion?

For the most part, penicillins are cleared by the kidneys through a process called tubular secretion.

They have pretty short half -lives, usually around 30 minutes to an hour.

Which means you'd have to dose them frequently to keep the levels up.

But there's a hack mentioned in the text.

Probenicid.

The probenicid hack.

This is pure pharmacology.

A lesson in competition.

Probenicid is a drug that uses the exact same transporter system in the kidney tubule to get excreted from the body.

So they're both trying to get through the same exit door.

Exactly.

If you give probenicid along with penicillin, the probenicid effectively hogs the transporter.

It clogs up the exit.

So it creates a little traffic jam.

A pharmacological traffic jam.

It keeps the penicillin from leaving the blood and entering the urine as quickly.

The result is you get higher levels of penicillin in the blood for a longer period of time.

Okay, let's break down the actual classes of penicillins.

The text groups them by their spectrum of activity.

First up, narrow spectrum.

This is your penicillin G and penicillin V.

They are the OGS.

They are very, very potent against gram -positive organisms like streptococci and meningococci.

They are also the drug of choice for spirochetes like treponema pallidum.

That's the bacteria that causes syphilis.

Correct.

And the text specifically notes that despite all our new fancy drugs,

penicillin G remains the king for treating syphilis.

It's still the best thing we have for it.

And the text differentiates G and V.

Yes.

Penicillin G is the injected form.

And there are these interesting formulations mentioned.

Procane penicillin G and benzathine penicillin G.

These are what we call depo forms.

Depo, meaning like a storage depo.

Exactly.

They are intramuscular injections.

But instead of the drug entering the blood instantly,

it forms a little reservoir in the muscle tissue and releases the drug slowly over time.

Benzathine penicillin G can release low levels for weeks.

Which is perfect if you have a patient who might not be reliable, who might not come back for a follow -up.

One shot and they are covered for a long time.

Exactly.

And penicillin V is just the oral acid stable version.

Okay.

So that's the narrow spectrum.

But then the bacteria started fighting back.

Which brings us to the penicillinase -resistant penicillins.

Right.

This is where the arms race really began in earnest.

Staphylococci in particular started producing an enzyme called penicillinase, or more broadly, beta -lactamate.

And this enzyme acts like a pair of molecular scissors.

Perfect description.

It finds that critical beta -lactam ring and it just snips it open.

And once the ring is open, the drug is completely useless.

Completely inert.

So chemists had to respond.

They developed drugs like napcillin, oxicillin, and dicloxacillin.

If you look at their chemical structure, they have a very, very bulky R -group side chain.

Like putting a big clunky shield on the side of the molecule.

Exactly.

It's a chemical principle called steric hindrance.

The side chain is so physically large that the bacterial enzyme simply can't get close enough to the ring to cut it.

The drug is protected by its own bulk.

The text mentions methicillin here, but it seems to be mostly in the context of mystery and resistance, not as a drug we use.

Yes.

Methicillin isn't used clinically anymore because it had a nasty habit of causing interstitial nephritis kidney inflammation.

But it gave its name to the most famous superbug, MRSA, methicillin -resistant Staphylococcus aureus.

And the text makes a pretty grim point here.

Bacteria that are resistant to methicillin are cross -resistant to napcillin and all the others in this group.

That's because MRSA didn't just learn to make better scissors, better beta -lactamases.

MRSA changed the lock itself.

It mutated its penicillin -binding protein, the target, so that these drugs can't bind to it at all anymore.

Scary stuff.

Okay, next group.

Extended spectrum.

Amoxicillin and ampicillin.

These are the ones everyone has heard of.

These are the workhorses of primary care.

They were chemically modified to be more hydrophilic, which allows them to pass through the foreign channels of gram negatives better.

So they cover the gram positives, but they also reach out to some gram negatives like E.

coli and hemophilus influenza.

And this brings us to that case study in box 38 .1, the 18 -month -old with the ear infection.

It's such a common scenario for any parent listening.

It is.

The trial has acute otitis media.

The doctor prescribes amoxicillin.

Why?

First, because it covers the likely bug -strap pneumo, H.

flu, moraxella.

Second, the text notes that it penetrates the middle ear fluid very well.

But notice the dosage disgust.

It's 90 mg daily.

That's a high dose.

It is a high dose.

Why the high dose?

Why not the standard dose?

The text explains it's because of the rise of streptococcus pneumonia with intermediate penicillin resistance.

The bacteria are becoming slightly resistant, altering their PVPs just a little bit.

So by flooding the system with a high dose, you can overwhelm that weak resistance and still bind enough PVPs to kill the bug.

It's a brute force approach.

But what if the bug in the ear is hemophilus influenza?

The text says it often produces beta -lactamase.

Then plain amoxicillin won't work.

The enzyme will chew it up before it can do anything.

You need a bodyguard.

And that's where we get to the beta -lactamase inhibitors.

I love the term the book uses.

Suicide inhibitors.

It is very descriptive, isn't it?

Clevulinate, sulbactam, and tazobactam.

These molecules are beta -lactams, structurally.

But, and this is the key point, they have almost no antibacterial activity themselves.

They don't kill bugs.

So why give them?

What's the point?

And to distract the enemy.

Imagine the beta -lactamase enzyme is a guard dog.

You throw it a steak laced with superglue.

The dog bites the steak.

The clavulinate in its jaws gets stuck.

It binds irreversibly.

The enzyme commits suicide by attacking the inhibitor.

And meanwhile, the amoxicillin just walks right past the neutralized dog and goes on to kill the bacteria.

Exactly.

That is the magic of augmentin, which is amoxicillin plus clavulinate.

We also see this with other combinations like ampicillin sulbactam and pipercillin tazobactam.

Speaking of pipercillin, that's the last class of penicillins listed.

The anti -pseudomonals.

The heavy hitter.

Pipercillin is effective against Pseudomonas aeruginosa, which is a notorious, very difficult to treat gram -negative bacteria, often found in hospitals and in patients who are immunocompromised.

So it's a step up.

A big step up.

It has even better penetration through porins.

It's often used for serious infections, intradominal sepsis, fibril neutropenia in cancer patients, that kind of thing.

Okay, we can't leave penicillins without talking about safety.

Everyone has been asked by a doctor, are you allergic to penicillin?

It is the most common cause of drug -induced hypersensitivity, absolutely.

But the text provides a statistic that might surprise you.

True penicillin allergy occurs in only 7 % to 23 % of patients who claim to have an allergy.

That's a huge gap.

Why the confusion?

Why do so many people think they're allergic when they're not?

A few reasons.

Maybe they had a viral rash as a kid that happened to occur while they were taking the drug and it got blamed.

Maybe they had an upset stomach, which is a side effect, not a true allergy.

But when the allergy is real, it acts as a hapten.

It binds to our own body proteins and triggers the immune system.

And this can range from a mild rash to...

To Ig -mediated anaphylactic shock, which is life -threatening.

Swelling, trouble breathing, drop in blood pressure.

And there's that weird mono rash mentioned in the chapter.

Yes.

This is a classic board exam question.

If you give ampicillin to a patient who has mononucleosis, which is a viral infection caused by EBV, they will almost certainly get a maculopapular rash.

The text says the frequency is over 90%.

So the doctor sees the rash and thinks, oh no, they're allergic to penicillin and puts it in their chart forever.

Exactly.

But, and this is the key point the book makes, it is not a true IgE -mediated allergy.

It's a different kind of reaction, mediated by sensitized lymphocytes reacting to the virus -drug interaction.

It does not mean they can't take penicillin in the future.

One last toxicity note from the text,

seizures.

Yes.

High concentrations of penicillins, especially in the CNS, can be irritating and lower the seizure threshold.

This is a risk primarily in patients with renal failure.

If the kidneys shut down, the drug level in the blood can spike to dangerous levels.

Okay, let's move to section four, the evolution,

the cephalosporins.

There's a huge, huge family of drugs,

and their origin story is great.

They were discovered in a fungus that was found near a sewage outlet off the coast of Sardinia, Italy.

From sewage to salvation, science is everywhere.

It is.

Chemically, they are similar to penicillins, they are beta -lactams, but they have a dihydrothiazine ring instead of the thiazolidine ring.

This little structural tweak makes them inherently more resistant to many beta -lactamases than the early penicillins were.

The text organizes them by generations.

It feels like software updates, version 1 .0, version 2 .0.

Let's walk through the evolution, first generation.

Cefazolin and ceflexin.

Think of these as similar to penicillin G, but a little broader.

They are excellent for gram -positive skin infections like staph and strep.

Cefazolin is the absolute go -to for surgical prophylaxis.

Prophylaxis meaning preventing an infection before it even happens.

Right, before a surgeon makes a cut, they give the patient IV Cefazolin to kill the bacteria on the skin so they don't get pushed into the wound during the surgery.

Okay, second generation.

The book lists cephatin and ceferoxym.

Now we start seeing the trade -off.

Yeah.

As we go up in generations, we start gaining ground on the gram negatives.

Cefatin is highlighted because it has activity against anaerobes like Bactroids fragilis, which live in our gut.

So very useful for abdominal surgeries.

Third generation, this seems to be where the big shift happens in the chapter.

Yes,

this is a huge leap.

Drugs like Ceftriaxone and Ceftazodime.

Here, we lose a little bit of that strong gram -positive power compared to the first gen, but we gain massive gram -negative power.

Ceftriaxone is an absolute superstar in modern medicine.

Why is it a superstar?

What's so special about it?

It's all about the pharmacokinetics.

It has a very long half -life, so it can be given just once a day, which is great for patients.

And unlike most others, it's excreted largely in the bile, not just the kidneys.

It penetrates the CNS well, making it a top choice for meningitis.

And it's also the drug of choice for gonorrhea and for Lyme disease.

That's a versatile drug.

And Ceftazodime.

Ceftazodime is the specialist in this generation for Pseudomonas.

Fourth generation, Cefame.

Maxipame.

This one tries to be the best of all worlds.

It penetrates bacteria rapidly.

It targets multiple PBPs.

It hits resistant gram negatives while trying to keep that good gram -positive coverage.

But the text puts a warning label on it.

A warning.

Yes.

It has been associated with higher all -cause mortality in some studies, possibly due to drug -induced encephalopathy.

Encephalopathy.

So brain dysfunction.

Yes.

Confusion, tremors, even coma.

Again, this is mostly a risk in patients with kidney issues, where the drug can accumulate to toxic levels.

And now we get to the advanced generation.

These sound very high -tech.

Ceftaraline and Cefitorcal.

Ceftaraline, brand name Teflero, is truly unique.

It is the only beta -lactam that is active against MRSA.

Wait, I thought we said MRSA changed the lock.

It mutated its PVP.

It did.

It has a mutated protein called PBP2A.

But Ceftaraline was specifically designed to fit that new mutated lock.

It binds to PBP2A.

It is a major, major breakthrough.

That's incredible.

And Cefitorcal.

This is for the nightmare scenario complicated UTIs, caused by bugs that have mutated their porins or have efflux pumps that spit other antibiotics out.

The text calls it a Cytophores cephalosporin.

Cytophore?

What does that mean?

It means iron carrier.

Bacteria eat iron to live.

Cefitorcal is designed to bind to iron, and the bacterium has an active transport system to pull iron into the cell.

Oh, I see where this is going.

The bacteria actively pumps the iron, and the drug that's attached to it, inside its own cell.

It's a Trojan horse strategy.

That is incredibly clever.

You tricked the bacteria into eating poison because it thinks it's food.

What about safety for this whole class?

If I'm allergic to penicillin, am I automatically allergic to cephalosporins?

This is a classic clinical dilemma.

The structures are similar.

The text states that cross -sensitivity is real, but it's low, about 5%.

So what's the rule of thumb?

The rule of thumb in the text is pretty clear.

If the patient had a mild reaction to penicillin, like a delayed itchy rash,

they probably won't react to a cephalosporin.

It's generally considered safe to give.

But if they had anaphylaxis, the throat closing, blood pressure dropping, shock reaction, you do not risk it.

The stakes are just too high.

Got it.

Okay, section five.

The heavy artillery.

Carbapenems and monobactams.

Let's start with the monobactam aztreonam.

It seems like an outlier.

Aztreonam is the specialist.

It's a monocyclic beta -lactam.

It only has one ring, not the fused double ring structure.

And its target is exclusively aerobic gram -negative rods, pseudomonas serratia.

It does absolutely nothing against gram -positives or anaerobes.

Why would you use such a specific narrow drug?

Because of the allergy issue we just discussed.

The text states it has almost NO cross -reactivity with penicillin allergies.

Its structure is different enough.

So if you have a patient with a history of severe penicillin anaphylaxis, who has a serious gram -negative infection,

aztreonam is your safe haven.

And then the carbapenems.

Imipenem, maripenem, urtipenem.

I called this gorillacillin in the outline because they seem to just smash everything.

The nickname fits.

They are the broadest -spectrum beta -lactams we have.

They are very resistant to many beta -lactamases.

We use them for serious mixed infections, endocarditis, pneumonia, sepsis where we don't know what the bug is yet and we just need to hit it hard.

But imipenem has a weird sidekick, right?

Silastatin.

You can't just give imipenem.

It's always given as imipenem -silastatin.

Why?

Yes.

Imipenem has an Achilles heel.

When it gets to the kidney, it is broken down by a human enzyme in the renal tubules called renal dehydropeptidase.

So our own body destroys the drug.

It does.

And the breakdown product is actually toxic to the kidney itself.

So it's a double fail.

Not ideal.

Not at all.

So we pair it with silastatin.

Silastatin does not kill bacteria.

Its only job is to inhibit that human renal enzyme.

It protects the imipenem so it can stay in the body and do its job.

It's important to note that maripenem and urtipenem don't need this.

They're stable on their own.

Any downsides to the gorillas?

Seizures.

Especially imipenem.

It lowers the seizure threshold more than other beta -lactams.

So you have to be very careful in patients with epilepsy or other CNS issues.

And ominously, the text notes that carbapenem resistance, bacteria that make carbapenemises, is a growing and very frightening problem.

We're seeing bugs that can eat even these drugs.

Which leads us to the final group.

The non -beta -lactam inhibitors.

Section 6.

We already mentioned their mechanisms, that assembly line sabotage, but let's talk about their clinical use.

Vancomycin.

Vancomycin is the heavy lifter for gram positives.

It is a huge molecule physically, so it's too big to fit through the poor ends of gram negatives.

It only kills gram positives.

It is the standard of care treatment for MRSA.

And the text also mentions it's the oral drug of choice for C.

difficile colitis.

Wait, didn't we just say vancomycin is a huge molecule?

Yeah.

Well, because of that, it is very poorly absorbed for the GI tract.

If you swallow vancomycin pill, almost none of it gets into your blood.

So why would you swallow it then?

Because C.

diff lives in the colon.

You want the drug to stay in the gut.

You swallow it, it travels down the pipe, killing the C.

diff along the way, and then just comes out in the stool.

It's a local treatment.

But for a systemic infection like MRSA in the blood or lungs, you must give it IV.

Oral won't work at all.

That is a crucial, crucial distinction.

Now the side effects.

Redneck syndrome.

Also called red man syndrome.

This happens if you infuse vancomycin too quickly through an IV.

It causes a massive non -allergic release of histamine from mast cells in the body.

So it looks like an allergy.

It mimics an allergy.

The patient turns bright red on their face, neck, and chest.

They get itchy.

Their blood pressure can drop.

But it is not a true allergy.

It's rate dependent.

You don't stop the drug forever.

You just slow down the infusion rate.

But there are real toxicities too, right?

Yes.

Nephrotoxicity, so kidney damage, and otopoxicity, which is hearing loss.

The text warns that we have to monitor drug levels in the blood very carefully.

Especially if the patient is also on other toxic drugs like aminoglycosides.

You can accidentally deafen a patient if you aren't paying attention.

There's a derivative mentioned too.

Televancin.

Yes.

Very similar to vancomycin used for skin infections.

It's a lepiglycopeptide, which means it has a fatty tail that helps it anchor to the bacterial membrane, making it more potent.

Then we have bacitracin.

Ah, Tracy.

It was isolated from a strain of bacillus subglyce that was found in the debrided tissue of a girl named Tracy back in 1945.

Poor Tracy.

Or famous Tracy, I guess.

A bit of both.

Bacitracin is highly nephrotoxic if injected systemically.

It essentially destroys the kidneys.

So we almost never inject it.

It is used topically.

You know those triple antibiotic appointments you put on a scrape?

Yeah, of course.

That's bacitracin.

It's safe on the skin because it doesn't get absorbed into the blood in any significant amount.

Finally, phosphamycin.

The one -shot wonder.

It's approved as a single large oral dose three grams for uncomplicated UTIs caused by E.

coli or enterococcus.

It gets absorbed, concentrates very highly in the urine, and kills the bugs.

It's popular because compliance is guaranteed.

You take one packet of powder, mix in water, and you're done.

Okay, let's wrap this up.

We've covered a lot of ground here.

We have.

We started with a cell envelope.

The difference between the thick sweater of gram positives and the armored sandwich of gram negatives.

We saw how the wall was built by those PVP construction workers and how beta -lactams sabotaged them.

Right.

And we walked through the penicillins, seeing how we had to modify them to fight stomach acid, then expand their spectrum, then protect them from beta -lactamases.

Then we evolved through the cephalosporin generations, trading gram positive power for gram -negative reach, all the way to that Trojan horse drug.

We saw the safety niche of Aztranem for allergic patients, the raw power of the carbapenems, and the specialized roles of vancomycin for MRSA and busotraycin just for the skin.

It's amazing to think that all of these drugs, this entire chemical arsenal, is focused on just one single thing.

Breaking a wall.

It really is.

But as we sign off, I want to leave you, the listener, with the thought from the very end of the chapter.

The text mentions the constant evolution of beta -lactamases, these ESBLs, the porin mutations.

We're in a biological arms race.

We invent a better wall breaker, they invent a better shield.

Or a better lock.

Or they build a pump to just throw the drug right back out of the cell.

Exactly.

The text leaves us with this palpable sense of urgency.

These drugs are miracles, but they're miracles with a shelf life.

And the question is, when the advanced generation isn't advanced enough,

what comes next?

That is the question every pharmacologist, every physician, and really every patient should be asking.

Thank you for listening to this deep dive into Chapter 38.

Thank you.

Thank you from the Last Minute Lecture Team.